[Federal Register: October 17, 2008 (Volume 73, Number 202)]
[Notices]
[Page 61909]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr17oc08-133]
[[Page 61909]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
registration under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on September 4, 2008,
Formulation Technologies LLC., 11400 Burnet Road, Suite 4010, Austin,
Texas 78758, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of Fentanyl
(9801), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance for
analytical characterization, secondary packaging, and/or for
distribution to clinical trial sites.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed
no later than November 17, 2008.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745), all applicants
for registration to import a basic class of any controlled substances
in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: October 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-24783 Filed 10-16-08; 8:45 am]
BILLING CODE 4410-09-P